Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 641-647, October 2008

Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study

  • Steven R. Goldsmith, MD

      Affiliations

    • Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationReprint requests: Steven R. Goldsmith, MD, Cardiology Division, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415.
    • ,
  • Uri Elkayam, MD

      Affiliations

    • University of Southern California, Los Angeles, California
    • ,
  • W. Herbert Haught, MD

      Affiliations

    • Huntsville Hospital, Huntsville, Alabama
    • ,
  • Abhijit Barve, MD, PhD

      Affiliations

    • Astellas Pharma US, Inc, Deerfield, Illinois
    • ,
  • Weizhong He, PhD

      Affiliations

    • Astellas Pharma US, Inc, Deerfield, Illinois

Received 19 December 2007; received in revised form 19 May 2008; accepted 2 June 2008. published online 11 July 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by Astellas Pharma US, Inc (formerly Yamanouchi Pharma America, Inc).

PII: S1071-9164(08)00178-4

doi:10.1016/j.cardfail.2008.06.003

Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 641-647, October 2008

Article Tools

* Image Usage & Resolution